Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Chinese Patients With Chronic Fibrosing ILDs With a Progressive Phenotype

Next Previous
X
Search
Trial Profile

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Chinese Patients With Chronic Fibrosing ILDs With a Progressive Phenotype

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Interstitial lung diseases; Pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 15 May 2024 Status changed from active, no longer recruiting to completed.
    • 30 Apr 2024 Planned End Date changed from 25 May 2024 to 7 May 2024.
    • 30 Apr 2024 Planned primary completion date changed from 14 May 2024 to 30 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top